본문 바로가기

Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
KOREAN JOURNAL OF INTERNAL MEDICINE32(4) · pp.656 · 2017
피인용
Web of Science 7Scopus 11KCI 0
FWCI (Scopus)
0.38
JCR IF
JCR 2016 1.729
ISSN
1226-3303

저자

  1. Hong, Young Joon제1저자Department of Cardiology, Chonnam National University Hospital, Gwangju, South Korea
  2. Jeong, Myung Ho교신저자Department of Cardiology, Chonnam National University Hospital, Gwangju, South Korea
  3. Bae, Jang HoDepartment of Cardiology, Konyang University Hospital, Daejeon, South Korea
  4. Oh, Seok KyuDepartment of Cardiology, Wonkwang University Hospital, Iksan, South Korea
  5. Rha, Seung WoonDepartment of Cardiology, Korea University Guro Hospital, Seoul, South Korea
  6. Hur, Seung HoDepartment of Cardiology, Keimyung University Dongsan Medical Center, Daegu, South Korea
  7. Lee, Sung YunDepartment of Cardiology, Inje University Ilsan Paik Hospital, Goyang, South Korea
  8. Kim, Sang WookDepartment of Cardiology, Chung-Ang University Hospital, Seoul, South Korea
  9. 차광수Department of Cardiology, Pusan National University Hospital, Busan, South Korea
  10. Chae, In HoDepartment of Cardiology, Seoul National University Bundang Hospital, Seongnam, South Korea
  11. Ahn, Tae HoonDepartment of Cardiology, Gachon University Gil Medical Center, Incheon, South Korea
  12. Kim, Kee SikDepartment of Cardiology, Daegu Catholic University Medical Center, Daegu, South Korea

초록

Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy end-point was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (-42.05 +/- 32.73 mg/dL vs. -34.23 +/- 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (-20.16 +/- 54.49 mg/dL in 4 mg group and -24.45 +/- 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (-0.13% +/- 1.21% in 4 mg group and -0.04% +/- 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

키워드

Myocardial infarctionAtherosclerosisLipidsHydroxymethylglutaryl-CoA reductase inhibitorsC-REACTIVE PROTEINRANDOMIZED CONTROLLED-TRIALAVERAGE CHOLESTEROL LEVELSSTATIN THERAPYGLUCOSE-METABOLISMCORONARY ATHEROSCLEROSISPLAQUE VOLUMEATORVASTATINDISEASEHYPERCHOLESTEROLEMIA

식별자

Scopus EID
2-s2.0-85025157051
WoS UID
000405512900010
KCI
ART002240842